Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05797740 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 367 to 366v15
  2. 4 versions Re-verified since Aug 8, 2025, no change to tracked fieldsv11-v14
  3. Enrollment target: estimated 360 to confirmed 367v10
  4. Trial status: Recruiting to Active, Not Recruiting Study sites: 34 to 30 · Primary and study completion dates: Aug 11, 2028 to Jan 31, 2029v9 Show 2 more changesShow less
    • Study sites: 34 to 30
    • Primary and study completion dates: Aug 11, 2028 to Jan 31, 2029
  5. Re-verified, no change to tracked fieldsv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 1 of 34 sitesv7
  2. Study sites: 33 to 34v6
  3. Re-verified, no change to tracked fieldsv5
  4. Study sites: 31 to 33v4
  5. Study sites: 30 to 31v3
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 26, 2023 to Aug 3, 2023 · Site details revised at 30 of 30 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of May 26, 2023 to Aug 3, 2023
    • Site details revised at 30 of 30 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck KGaA
43 trials monitored
See 4 trials at risk
Multiple Sclerosis
991 trials monitored
See 36 trials at risk
This study aims to describe participants characteristics that can predict the safety and effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world setting.
Trial Details
NCT Number NCT05797740
Lead Sponsor Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions Multiple Sclerosis
Enrollment 366 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov